Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.

05/20/2026, 9:50 AM • Benzinga

Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy

Avaí Bio and Austrianova announced completion of a GMP Master Cell Bank containing genetically modified cells that overexpress the α-Klotho protein. The MCB will undergo comprehensive viral and contamination testing to meet FDA regulatory standards. Upon successful completion, the companies will generate a Working Cell Bank to manufacture the final Cell-in-a-Box encapsulated clinical product for treating age-related disorders.

05/20/2026, 8:45 AM • Benzinga

Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference

Avaí Bio, Inc. (OTCQB: AVAI) and its joint venture partner Austrianova announced they will present latest data on their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September. The presentation will focus on production of the longevity protein from encapsulated cells using Cell-in-a-Box® technology, designed to restore circulating α-Klotho levels for therapeutic applications in aging and related conditions.

04/07/2026, 8:00 AM • Benzinga

The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step

The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.

03/31/2026, 8:49 PM • Benzinga

Scalable Biotech Manufacturing Unlocks a $14B Market

The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaí Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.

03/27/2026, 9:15 AM • Benzinga

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

Avaí Bio announced a critical milestone in creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, an anti-aging protein that declines by 50% after age 40. The company is partnering with Austrianova to use Cell-in-a-Box encapsulation technology for its Klothonova anti-aging and Insulinova diabetes programs. This development occurs as the cell and gene therapy market expands rapidly, with the sector forecast to grow from $10.4 billion to over $45 billion by 2035.

03/24/2026, 11:05 AM • Benzinga

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.

03/18/2026, 10:00 AM • Benzinga

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.

01/29/2026, 1:31 PM • Benzinga

Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium

Avant Technologies (OTCQB: AVAI), a biotechnology company focused on cell-based therapies for diabetes, announced its participation in the 15th European Pancreas and Islet Transplantation Association (EPITA) Symposium in Austria. The company is evaluating advanced cells for diabetes therapy using its Cell-in-a-Box® microencapsulation technology, developed with partner SGAustria, which offers immunosuppression-free protection for transplanted insulin-producing cells.

01/26/2026, 8:30 AM • Benzinga

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.

01/23/2026, 12:56 PM • GlobeNewswire

Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize

The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating significant efficacy and safety profiles.

01/02/2026, 1:29 PM • Benzinga

AVANT Announces Strategic Growth Investment from Court Square Capital Partners and Pamlico Capital

AVANT, a technology services distributor, has formed a strategic partnership with Court Square Capital Partners, with continued investment from Pamlico Capital. The partnership aims to support AVANT's growth and enhance its capabilities for serving Trusted Advisors in IT decision-making.

12/17/2025, 1:00 PM • GlobeNewswire

Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment

Avant Technologies and SGAustria formed a joint venture to develop innovative cell encapsulation technology for diabetes treatment, aiming to create a potential functional cure by protecting genetically modified insulin-producing cells from immune system rejection.

12/16/2025, 8:15 AM • Benzinga

THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis

The market is shifting focus towards technologies that can detect previously invisible threats across healthcare, resource exploration, and diagnostics, with several companies developing innovative solutions for cardiac care, diabetes treatment, cancer therapy, and mineral exploration.

12/15/2025, 10:54 AM • GlobeNewswire

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

Market intelligence report highlighting five undervalued companies across biotech, AI, defense, gold exploration, and medical technology sectors, suggesting significant potential for valuation growth due to technological innovations and strategic positioning.

12/06/2025, 1:51 PM • GlobeNewswire